Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01345136 · ClinicalTrials.gov registry record · Phase 2
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT01345136 is a Phase 2 study that was terminated before completion, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 4 participants.
The verdict
NCT01345136, a Phase 2 study, was terminated before completion, sponsored by Jonsson Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if RAD001 treatment will shrink or slow the growth of the vestibular schwannoma(s) in Neurofibromatosis 2 (NF2) patients. Secondary objectives include determining if RAD001 treatment will improve hearing ability in NF2 patients. RAD001 is an oral drug that is approved by Food and Drug Administration (FDA) for other types of tumors, it is not approved by the FDA for treatment of NF2 related tumors.
Interventions
- DRUG RAD001, everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-07-01 |
| Est. Completion | 2024-02-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01345136
The ClinicalTrials.gov registry entry for NCT01345136 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RAD001, everolimus is the first listed.
NCT01345136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01345136 about?
NCT01345136 is a clinical study titled "Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma". The purpose of the study is to determine if RAD001 treatment will shrink or slow the growth of the vestibular schwannoma(s) in Neurofibromatosis 2 (NF2) patients. Secondary objectives include determining if RAD001 treatment will improve hearing ability in NF2 patients. RAD001 is an oral drug that i...
What is the current status of trial NCT01345136?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2015-07-01. Estimated completion is 2024-02-06.
What interventions are being tested in trial NCT01345136?
The interventions under investigation include: RAD001, everolimus (DRUG).
Who is sponsoring clinical trial NCT01345136?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.